AstraZeneca ties up with Emergent BioSolutions to make COVID-19 vaccine in U.S.

The deal comes weeks after the United States pledged up to $1.2 billion to secure 300 million doses of AstraZeneca’s vaccine, which is among the first to move into mid-stage trials. AstraZeneca has said that the first indication of the effectiveness of its vaccine would likely be available in June or July. …read more

Source:: Yahoo Finance

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.